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Lactate
The inhibition of DNA polymerase-y impairs the synthesis
of mitochondrial enzymes and leads to the dysfunction of
the respiratory chain and the accumulation of acetyl-CoA
within the mitochondria. This build-up of acetyl-CoA shifts
the balance of pyruvate metabolism towards lactate
reduction. The result is the accumulation of lactate in the
blood (Fig. 2).'-'
Fig. 1. Aerobic oxidative phosphorylation.
the doors to a competitive market in generic drugs in the
developing world as a way to deal with the epidemic in a
sustainable manner. He noted that pilot HAART projects
using generic drugs that combine prevention and
treatment, such as the one conducted by Medecins Sans
Frontieres in Khayelitsha (Abstracts 1095 and 36851. have
proved that HAART can be feasible in limited-resource
settings and should be expanded. Achmat lives with HIV
and has free access to antiretrovirais, yet he declared he
would not take the lifesaving drugs until the South African
government agreed to an action plan to provide HAART in
the public hospitals in South Africa.





Since the advent of highly active antiretroviral therapy
(HAARl]. the prognosis of patients with HIV infection has
improved dramatically - as evidenced by the decrease in
mortality and morbidity rates.' However, this increase in
life expectancy carries the risk of significant drug
toxicities, such as the nucleoside reverse transcriptase
inhibitor (NRTI]-associated mitochondrial toxicity.
Mitochondria are organelles which are present in all cells
except erythrocytes. They generate cellular energy in the
form of adenosine triphosphate (ATP) by aerobic oxidative
phosphorylation (Fig. 1). This process is dependent on DNA
polymerase-y, an enzyme that replicates the major
components of mitochondrial DNA2.3
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CASE 1: ASYMPTOMATIC HYPERLACTATAEMIA
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CASE 2: SYMPTOMATIC LACTIC ACIDOSIS WITH
RECOVERY
She presented at week 32 with a 2-week history of nausea,
vomiting and epigastric pain. She was treated for
gastroenteritis. Liver function tests showed a mild
transaminitis and an elevated LDH level. She returned at
week 33 with ongoing gastrointestinal (Gin symptoms and
a worsening of the biochemical abnormalities [Fig. 4).
She has been clinically well since then. Her lactate levels
have remained normal on continued therapy.
A 34-year-old woman (height 163 cm, weight 87 kg,
BMI 33) was commenced on therapy with a protease
inhibitor/d4T 4D mg twice a day/3TC 150 mg twice a day.
The baseline viral load was 54 600 copies/ml and the









The patient was admitted at week 34 with ongoing GIT
symptoms. dyspnoea and paraesthesiae. Her lactate level
was 9.1 mmol/l and arterial blood gas measurement
revealed a metabolic acidosis: pH 7.3/partial pressure
carbon dioxide (pCO,) 1.5 kPa/partial pressure oxygen (pO,)
8.4 kPa/standard bicarbonate (SB) 5.9 mmol/1. She was
diagnosed with lactic acidosis. She had stopped her HMRT
on admission. Her symptoms settled by week 35 and she
was discharged.
Fig. 4. Changes over time ofbiochemical parameters in case 2.
As she was asymptomatic. her lactate levels were
monitored over the next 6 weeks. This demonstrated a
linear increase in lactate (Fig. 3). Based on the rate of rise.
it was predicted that her lactate levels would soon reach 10
mmol/1. As the mortality rate associated with a lactate level
>10 mmol/l is 800/a, she was changed to a non-d4T-NRTI
regimen at week 59. The biochemical abnormalities settled
on the new therapy.
levels. This biochemical picture raised suspicions of an
increase in lactate. Her lactate level was measured at week
52 and found to be elevated at 2.4 mmol/l [upper limit of
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At week 48, she was noted to have an asymptomatic
increase in transaminase and lactate dehydrogenase (LDH)
The resultant mitochondrial dysfunction may manifest
biochemically as hyperlactataemia and lactic acidosis or
clinically as hepatic steatosis, pancreatitis, peripheral
neuropathy and myopathy.
Fig. 2. Inhibition of DNA polymerase-v and shift to lactate
praduction.
A 29-year-old woman (height 169 cm, weight 106 kg, body
mass index (BMI) 37) was commenced on therapy with a
protease inhibitor/ddl 4D0 mg 4 times a day/d4T 4D mg
twice a day. The baseline viral load was 26 000 copies/ml
and the baseline CD4 count 279M
The toxicity of NRTls is related to their antiretroviral
mechanism of action: the selective inhibition of viral DNA
replication. If the selectivity of the NRTI is not absolute,
cellular targets such as mitochondrial DNA polymerase-v
will be affected.'"
All currently available NRTls inhibit human mitochondrial
DNA polymerase-v to some degree. The relative potency of
inhibition of DNA polymerase-v by NRTls is as follows:
zalcitabine > didanosine > stavudine > lamivudine >
zidovudine > abacavir.~' Abacavir has avery low affinity for
mitochondrial DNA polymerase-v.' The risk for developing
NRTI-related mitochondrial toxicity increases with length
of time on therapy.'
The following three cases illustrate the spectrum of
hyperlactataemia.
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CASE 3: SYMPTOMATIC LACTIC ACIDOSIS
RESULTING IN PATIENT DEATH
A 34-year-old woman (height 158 cm, weight 75 kg, BMI
30) was commenced on nelfinavir 1250 mg twice aday/ddl
400 mg 4 times a day / d4T 40 mg twice a day.
The baseline viral load was 547 152 copies/ml and the
baseline CD4 count 125M
The initial regimen failed virologically and the patient was
changed to indinavir 800 mg twice a day/RN 100 mg twice
a day/ddl 400 mg 4 times a day/d4T 40 mg twice a day,
based on viral genotyping.
She was fully suppressed (viral load < 50 copies/m I) and
clinically well after 24 weeks of therapy.
She presented at week 32 with a 2-day history of nausea,
vomiting and epigastric pain. She had suffered an episode
of diarrhoea during the previous week. She was admitted
with suspected acute pancreatitis. She had stopped taking
her HAART before admission.
Arterial blood gas measurement revealed a partially
compensated metabolic acidosis: pH 7.29/pO, 16.23 kPa/pCO,
1.98 kPa/SB 7.3 mmol/I. Her lactate level was reported as
21.6 mmol/I. She was diagnosed with lactic acidosis and
admitted to the ICU. Aggressive supportive therapy -
including intravenous rehydration, intravenous sodium
bicarbonate and parenteral vitamin B, including riboflavin
- was instituted. She did not respond to these measures
and died 2 days later due to lactic acidosis.
CLINICAL SYNDROMES
Hyperlactataemia or lactic acidosis can be manifestations
of NRTI-induced mitochondrial toxicity.
HYPERLACTATAEMIA: CASE 1
This elevation in serum lactate (venous lactate
> 2.0 mmol/I) in the absence of metabolic acidosis (arterial
pH < 7.3) can be asymptomatic or symptomatic.
The symptoms may include fatigue, asthenia, malaise, GIT
symptoms (loss of appetite, loss of weight, nausea,
vomiting, abdominal pain, dyspepsia ± bloating), dyspnoea
and neurological symptoms (paraesthesiae, muscle
weakness). An elevated LDH level, mild transaminitis and a
decrease in bicarbonate often precede the onset of
symptoms."
The reported incidence of asymptomatic hyperlactataemia
in NRTI-treated patients ranges from 8% to 21''10, while
that for symptomatic hyperlactataemia is only 1 - 2%."·"
At present we are unable IQ predict which patients with
asymptomatic hyperlactataemia will go on to develop lactic
acidosis." However, recent literature reviews have reported
an increased risk in female patients" and patients with an
increased BMI.'·" This trend is supported by our three cases.
Deficiencies in ribofiavin and thiamine, cofactors required
for oxidative phosphorylation, may further predispose
patients to the development of hyperlactataemia';
LACTIC ACIDOSIS: CASES 2 AND 3
This symptomatic elevation in serum lactate accompanied
by metabolic acidosis is often associated with a mild
transaminitis and a rise in LDH" Liver biopsy reveals
hepatic steatosis.
The reported rate of lactic acidosis varies from 0.85 cases
per 1 000 patient-years of treatment" to 8.4 cases/l 000
patient-years," with an even higher rate reported among
patients taking only stavudine and didanosine." There are
some indications that the rate may be even higher in South
African patients." Although development of lactic acidosis
is not a frequent event, it is important because of the
associated high mortality rate, which approaches 80% in
patients with a serum lactate level> 10 mmol/I.'
MANAGEMENT
Routine monitoring of lactate levels is not recommended
for all patients receiving NRTls.' However, Adda et al."
propose a diagnostic index for monitoring patients on
therapy and predicting the occurrence of hyperlactataemia.
This index includes an elevated LDH level (> 2 x ULN)
together with elevated transaminases (aspartate
aminotransferase (ASn and/or alanine aminotransferase
[ALn > 2 x ULN) and the presence of nausea and/or
vomiting. This index showed WOOfo sensitivity, 98%
specificity, 100% negative predictive value and 50%
positive predictive value for hyperlactataemia.
Patients who manifest persistent symptoms, signs or
laboratory abnormalities (transaminitis/raised LDH)
suggestive of hyperlactataemia should be evaluated with
venous lactate sampling.
Further management depends on the absolute lactate level
and the relationship of the abnormality to the underlying
symptom(s). The strategy outlined in Table I has been
proposedH
Before attributing hyperlactataemia or lactic acidosis solely
to the use of NRTls, other causes of metabolic acidosis need
to be ruled out, including sepsis/uraemia/diabetic
ketoacidosis/thyrotoxicosis/lymphoma."
Once the diagnosis of NRTI-related mitochondrial toxicity
is made, NRTI therapy should be stopped. Cessation of
treatment should lead to the resolution of symptoms."""
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TABLE I. PROPOSED STRATEGY FOR INTERPRETING LACTATE
LEVELS
As HAART becomes more affordable and accessible, so
NRTI-associated mitochondrial toxicity will probably
become more prevalent It therefore becomes increasingly
ffHRUARY 2003
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important for clinicians to be aware of these rare but
potentially life-threatening drug toxicities and the need to
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Further treatment is largely supportive. Hyperlactataemia
can be managed on an outpatient basis, but patients with
lactic acidosis require hospitalisation with aggressive
intravenous rehydration and alkalinisation with high-dose
bicarbonate infusions'
Brinkman et al." propose twice-daily vitamin supple-
mentation for the treatment of lactic acidosis, including 50
mg thiamine/lO mg riboflavin/lOO mg nicotinamide/la mg
pyridoxine/lO mg dexpanthenol/100 mg intravenous
l-carnitine. The regimen is continued until serum lactate
levels fall below 3 mmol/1.
On recovery from hyperlactataemia or lactic acidosis,
rechallenge with NRTI-sparing regimens is preferred."
However, in cases of moderate hyperlactataemia there have
been reports of rechallenge with non-d4T NRTI-containing
regimens, which were not associated with relapse.""" In
both situations, careful monitoring of clinical and
biochemical status is required.
A recent case series has shown that specific therapy using
the cofactors of oxidative phosphorylation (thiamine,
riboflavin, l-carnitine, prostaglandin E and coenzyme Q)
are associated with a lower mortality rate." This supports
previous anecdotal information of patients with lactic
acidosis who responded dramatically to administration of
essential cofactors: high-dose riboflavin 50 mg once daily,
thiamine 100 mg by intravenous infusion, or l-carnitine
50 mg/kg daily respectively."·"
